Dr. Matthias Gotte, Associate Professor in Biochemical Virology at McGill's Department of Microbiology and Immunology, said that HIV/herpes co-infection rates are very high and carry significant health burdens for those patients who are already coping with HIV.
"In co-infected individuals, HIV disease progression is enhanced by the presence of herpes. Why this is the case is not clear, but there's a lot of evidence for it. Moreover, if you're infected with HIV and herpes, it makes it easier for you to transmit HIV to other people. And if you're infected with herpes alone, it makes it easier for you to acquire HIV," he said.
Though researchers previously long believed that acyclovir was an ineffective drug against HIV, it was often prescribed to co-infected patients in the hope of indirectly treating HIV by reducing the herpes load.
However, the NIH team found that in the presence of herpes virus HHV-6, acyclovir actually attacks HIV directly and is able to suppress its reproduction.
Acyclovir is a 'prodrug,' which is converted into its active form only after it is administered to a patient.
The researchers have shown that the herpes virus contains an enzyme not present in HIV and it is this enzyme that converts acyclovir into a compound capable of attacking in HIV.
Acyclovir by itself is simply inactive against HIV and therefore the drug can only work in people infected with both viruses.
The researchers hope that this discovery may open a new front in the war on HIV, particularly in parts of the developing world where rates of co-infection are extremely high.
"No anti-retroviral kills HIV completely. We need to administer at least three drugs to hold it in check. This potentially gives us another weapon in the armory, and it's cheap and accessible, which matters a lot in the developing world," Dr. Gotte said.
The study was published in the Sept. 11 issue of the journal Cell Host and Microbe.